Overview
OLMA market data
Price History
OLMA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.87 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.96 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.91 – $36.26 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $919.6M · P/B 4.11.
Company News
JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46Benzinga · Aug 13, 2026, 3:28 PM
8-K filing — Olema Pharmaceuticals, Inc. (OLMA)SEC EDGAR · Aug 13, 2026, 11:05 AM
Olema Oncology Announces Appointment Of Jason O'Byrne As CFOBenzinga · Aug 13, 2026, 11:05 AM
Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59Benzinga · Aug 11, 2026, 7:28 PM
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027Benzinga · Aug 11, 2026, 6:27 PM
Olema Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 EPS results. Also, HC Wainwright & Co. lowered its price target on the stock from $38 to $36.Benzinga · Aug 11, 2026, 2:28 PM
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $36Benzinga · Aug 11, 2026, 12:38 PM
OppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market SessionBenzinga · Aug 11, 2026, 12:04 PM
Olema Pharmaceuticals Q2 EPS $(0.61) Misses $(0.55) EstimateBenzinga · Aug 10, 2026, 8:29 PM
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate CancerGlobenewswire Inc · May 26, 2026, 11:15 AM